Author

K. Hopp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

E. T. Clambey· 3 shared R. A. Nemenoff· 3 shared A. J. Neuwelt· 2 shared A. M. Johnson· 2 shared B. L. Bullock· 2 shared H. Y. Li· 2 shared J. M. Poczobutt· 2 shared J. W. Kwak· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. T. Clambey

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Immune Checkpoint Activity Regulates Polycystic Kidney Disease Progression

E. K. Kleczko, D. T. Nguyen, K. H. Marsh, C. D. Bauer, A. S. Li, S. B. Furgeson, B. Y. Gitomer, M. B. Chonchol, E. T. Clambey, K. A. Zimmerman, R. A. Nemenoff, K. Hopp

This study investigates immune checkpoint activity in ADPKD, finding that dual checkpoint inhibition improves disease outcomes in adult-onset models.

bioRxiv · Apr 24, 2022Immunology

Cancer Cell Intrinsic Expression of MHCII Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma

A. M. Johnson, B. L. Bullock, A. J. Neuwelt, J. M. Poczobutt, R. E. Kaspar, H. Y. Li, J. W. Kwak, K. Hopp, M. C. M. Weiser-Evans, L. E. Heasley, E. L. Schenk, E. T. Clambey, R. A. Nemenoff

This study shows that cancer cell expression of MHCII affects T cell infiltration and response to anti-PD-1 therapy in lung adenocarcinoma.

bioRxiv · Jan 9, 2020 · PreprintCancer Biology

CpG-creating Mutations are Costly in Many Human Viruses

V. R. Caudill, S. Qin, R. Winstead, J. Kaur, K. Tisthammer, E. G. Pineda, O. Carja, R. M. Eggo., K. Koelle, K. Lythgoe, S. Roy, N. Allen, M. Aviles, B. A. Baker, W. Bauer, , Wint

The paper examines the cost of CpG-creating mutations in various human viruses using existing genomic data and finds they are generally costly.

bioRxiv · Jul 25, 2019Evolutionary Biology

Tumor-Intrinsic Response to IFNgamma Shapes the Tumor Microenvironment and Anti-PD-1 Response in NSCLC

B. L. Bullock, A. K. Kimball, J. M. Poczobutt, H. Y. Li, J. W. Kwak, A. J. Neuwelt, A. M. Johnson, E. Kleczko, R. Kaspar, K. Hopp, E. Schenk, M. C. Weiser-Evans, E. T. Clambey, R. A. Nemenoff

This study identifies tumor-intrinsic IFN-gamma signaling as a determinant of anti-PD-1 response in NSCLC by altering the tumor microenvironment.

bioRxiv · Jan 27, 2019Cancer Biology